Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Capital Expenditures (2016 - 2024)

Fortress Biotech (FBIO) has 11 years of Capital Expenditures data on record, last reported at -$1.4 million in Q3 2024.

  • For Q3 2024, Capital Expenditures fell 139600.0% year-over-year to -$1.4 million; the TTM value through Sep 2024 reached $28000.0, down 77.78%, while the annual FY2023 figure was $63000.0, 97.68% down from the prior year.
  • Capital Expenditures reached -$1.4 million in Q3 2024 per FBIO's latest filing, down from $1.4 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.3 million in Q3 2021 and bottomed at -$1.4 million in Q3 2020.
  • Average Capital Expenditures over 5 years is $409722.2, with a median of $63500.0 recorded in 2022.
  • The widest YoY moves for Capital Expenditures: up 8618.75% in 2024, down 139600.0% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at -$286000.0 in 2020, then skyrocketed by 784.27% to $2.0 million in 2021, then plummeted by 95.35% to $91000.0 in 2022, then tumbled by 69.23% to $28000.0 in 2023, then crashed by 5082.14% to -$1.4 million in 2024.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$1.4 million in Q3 2024, $1.4 million in Q2 2024, and $28000.0 in Q4 2023.